Loading organizations...

§ Public · Austin, TX, USA
Lumos Pharma is a technology company.
Lumos Pharma is a clinical-stage biopharmaceutical company developing oral therapeutics for rare diseases. Its lead product, LUM-201, an investigational oral ghrelin mimetic, stimulates growth hormone secretion. This targets Pediatric Growth Hormone Deficiency (PGHD), offering a non-injectable alternative that simplifies long-term management for patients using daily injections.
Founded in 2014, Lumos Pharma's structure arose from a strategic merger, uniting a management team experienced in rare disease and endocrinology drug development. The company's inception came from the insight that oral therapies could significantly advance endocrine disorder treatment, offering a less burdensome option than injectable regimens.
Lumos Pharma serves patients with rare endocrine conditions, primarily children with Pediatric Growth Hormone Deficiency. Its vision is to improve lives by developing and commercializing novel rare disease treatments. The company aims to be a leading provider of specialized medications, dedicated to efficient development and effective therapies for unmet medical needs.
Lumos Pharma has raised $48.0M across 2 funding rounds.
Lumos Pharma has raised $48.0M in total across 2 funding rounds.
Lumos Pharma has raised $48.0M in total across 2 funding rounds.
Lumos Pharma's investors include Cameron Wheeler, Santé Ventures, Clarus Ventures, New Enterprise Associates, Roche, UCB Ventures.
Lumos Pharma has raised $48.0M across 2 funding rounds. Most recently, it raised $34.0M Series B in April 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2016 | $34M Series B | Cameron Wheeler | Santé Ventures, Clarus Ventures, NEW Enterprise Associates, Roche, UCB Ventures | Announced |
| Feb 1, 2014 | $14M Series A | NEW Enterprise Associates, Santé Ventures | — | Announced |
Lumos Pharma is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for rare diseases—particularly Pediatric Growth Hormone Deficiency (PGHD)—with its lead candidate LUM-201 (ibutamoren) in Phase 2/clinical development as an oral growth‑hormone secretagogue alternative to injectable recombinant growth hormone[4][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biopharma Landscape
Quick Take & Future Outlook
Quick take tie‑back: Lumos Pharma has carved a focused, patient‑centered niche in rare pediatric growth disorders by advancing an oral GH secretagogue through coordinated clinical programs and orphan designations—its near‑term prospects hinge on upcoming trial readouts that will determine whether an oral alternative can meaningfully disrupt years of injectable GH therapy[1][4][2].
Sources: company pages, clinical program listings and event profiles describing Lumos’s focus, trials and leadership[1][4][3][2].